considered dual inhibition of HDAC and BTK resulting in long-term remission with R/R DLBCL patients after failure of CAR-T cell therapy with TP53 mutation, which suggests underlying synergistic mechanism between BTK inhibitor and CAR-T cell therapy (7). Here, TP53 is linked to diffuse large B-cell lymphoma.